Author + information
- Received March 24, 2009
- Revision received June 1, 2009
- Accepted June 15, 2009
- Published online September 1, 2009.
- Jennifer Franke, MD⁎,⁎ (, )
- Bernhard Reimers, MD†,
- Marta Scarpa†,
- Simonetta Span†,
- Marcus Thieme, MD‡,
- Nina Wunderlich, MD⁎,
- Dierk Scheinert, MD‡ and
- Horst Sievert, MD⁎
- ↵⁎Reprint requests and correspondence:
Dr. Jennifer Franke, CardioVascular Center Frankfurt, Seckbacher Landstrasse 65, 60389 Frankfurt, Germany
Objectives We sought to examine the acute and subacute results of carotid stenting performed during live transmissions.
Background Teaching courses focusing on live demonstrations of carotid interventions have been the key educational facility for physicians interested in learning state-of-the-art interventional techniques of carotid stenosis treatment. However, starting with the very first live demonstration of interventional procedures, there has been an ongoing discussion whether patients treated during live transmissions are at higher risk.
Methods Between March 1, 2001, and June 30, 2008, 186 high-grade lesions of the internal carotid artery in 186 patients have been treated by stent implantation during live transmissions to 22 interventional conferences at 3 high-volume centers. Technical success was defined as the ability to perform carotid stent implantation. The combined end point of death, major stroke, minor stroke, or myocardial infarction was defined as primary end point.
Results The procedure was technically successful in 185 of 186 (99.5%) interventions. Seventeen patients had 1 of the following acute in-hospital complications: major stroke in 2 (1.1%), minor stroke in 3 (1.6%), transient ischemic attack in 11 (5.9%), and amaurosis of the ipsilateral eye due to an occlusion of the retinal artery in 1 (0.5%). None of the patients died, and no myocardial infarctions occurred. The composite primary end point occurred in 6 (3.2%) patients.
Conclusions In this consecutive series of carotid stent cases performed by expert operators during live demonstration courses, the procedural and 30-day clinical outcomes were similar to the results appearing in the contemporary published data.
Dr. Sievert reports having ownership interest in Lumen Biomedical and serving as a consultant for Kensey Nash, Lumen Biomedical, EndoTex, ev3, Gore, and Invatec. This study was performed in compliance with human studies committees of the authors' institutions. Written informed consent for treatment and live transmission of the procedure was received from all patients before the procedure.
- Received March 24, 2009.
- Revision received June 1, 2009.
- Accepted June 15, 2009.
- American College of Cardiology Foundation